Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales)-Reference-Cited by-同舟云学术

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales)

Published:2021-11 Issue: Volume:158 Page:1-11
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Cancel Mathilde^ORCID,Fromont Gaelle,Blonz Cyriac,Chevreau Christine,Rioux-Leclercq Nathalie,Laguerre Brigitte,Oudard Stéphane,Gross-Goupil Marine,Gravis Gwenaelle,Goldwasser François,Rolland Frédéric^ORCID,Delva Rémy,Moise Laura,Emambux Sheik^ORCID,Vassal Cécile,Zanetta Sylvie^ORCID,Penel Nicolas,Fléchon Aude,Barthélémy Philippe,Saldana Carolina^ORCID,Lefort Félix,Escudier Bernard,Linassier Claude^ORCID,Albiges Laurence

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours;Moch;Eur Urol,2016

2. Predicting oncologic outcomes in renal cell carcinoma after surgery;Leibovich;Eur Urol,2018

3. Characterizing the outcomes of metastatic papillary renal cell carcinoma;Connor Wells;Cancer Med,2017

4. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria;Kroeger;Cancer,2013

5. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis;Escudier;Eur J Cancer,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort;European Journal of Cancer;2024-07

2. High MICAL-L2 promotes cancer progression and drug resistance of renal clear cell carcinoma cell via stabilization of ACTN4 and following vimentin expression;2024-06-25

3. Enhanced Reendothelialization and Thrombosis Prevention with a New Drug-Eluting Stent;Cardiovascular Drugs and Therapy;2024-06-04

4. Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies;Kidney Cancer;2023-10-10

5. Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials;Current Treatment Options in Oncology;2023-07-06